Citius Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Citius Pharmaceuticals

14/05/2024 23:02

* Citius Pharmaceuticals Inc  CTXR.OQ  reported a quarterly
adjusted loss of 5 cents​​ per share for the quarter ended in
March, higher than the same quarter last year, when the company
reported EPS of -7 cents.  The lone analyst forecast for the
quarter was for a loss of 6 cents per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Citius Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 5 cents​.
    * The company reported a quarterly loss of $8.54 million.
    * Citius Pharmaceuticals Inc shares had fallen by 22.5% this
quarter and lost 8.1% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 123.1% in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Citius
Pharmaceuticals Inc is $4.00 
This summary was machine generated from LSEG data May 14 at
10:02 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.06          -0.05          Beat
 Dec. 31 2023      0.13           -0.06          Missed
 Sep. 30 2023      -0.02          -0.08          Missed
 Jun. 30 2023      -0.05          -0.06          Missed